Glomerulonephritis – Current Treatment – Current Treatment: Physician Insights – Glomerulonephritis (US)
Glomerulonephritis (GN) is a condition involving inflammation of the glomerulus, which plays an important role in the filtration of blood into the kidney. If the glomerulus becomes inflamed and damaged, there can be a decline in kidney function, leading to chronic kidney disease (CKD). While mild GN cases may not require drug intervention, severe cases are managed with therapies like corticosteroids and immunosuppressants. This content delves deep into the dynamics of the GN therapy market, examining the management of GN patients from the perspective of nephrologists. We focus on how GN disorders, such as immunoglobulin A (IgA) nephropathy, focal segmental glomerulosclerosis (FSGS), lupus nephritis (LN), and membranous nephropathy (MN), are being treated in the United States today and the factors behind those treatment decisions.
Questions answered
- What are U.S. specialists’ attitudes and perceptions regarding the diagnosis and management of patients with IgAN, FSGS, LN, or MN?
- What percentage of GN patients are prescribed pharmacotherapy?
- What are the key drug classes that nephrologists use to manage patients with GN?
- How does treatment differ for patients with IgAN, FSGS, LN, or MN?
- How do nephrologists adjust pharmacotherapy in response to disease progression?
Content highlights
- Geography: United States
- Primary research: survey of 102 U.S. nephrologists
- Key drugs covered: RAAS inhibitors, corticosteroids, immunosuppressants
- Key insights provided:
- Factors influencing disease management and treatment decisions
- Drivers and constraints of treatment selection
- Physician-reported treatment practices and brand-level patient shares
- Rationale for changes in treatment approach
- Physician insight on persistency and compliance
- Physician-reported recent / anticipated changes in brand usage or treatment approach
Product description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
